July 2020

Clarendon portfolio company Stormharvestor the Belfast-headquartered green technology firm has today announced the conclusion of a €2 million investment round and plans to launch a major recruitment drive. The new investment will allow StormHarvester to accelerate the international roll-out of its ground-breaking technology. In 2019 StormHarvester expanded into 19 new markets through a partnership deal […]

Clarendon portfolio company B-Secur and LifeQ announced today a collaboration to offer an advanced, integrated Electrocardiogram (ECG) and optical Photoplethysmography (PPG) based technology solution. The combined offering will provide superior sensing capabilities from wearable devices and enable advanced features for identification, wellness and health monitoring in next generation everyday devices. Each company is widely recognised

Clarendon portfolio company BrainWaveBank Limited an artificial intelligence (‘AI’) company focused on developing a machine learning-enabled neurocognitive platform for in-home assessment and remote monitoring of central nervous system disorders, including neurodegenerative diseases such as Alzheimer’s, and psychiatric conditions such as depression and schizophrenia, announces the closing of a £1.1m financing round led by Par Equity and supported by

Belfast, 21 July, 2020: Clarendon portfolio company Neurovalens, a global healthtech company headquartered in Belfast and San Diego, has raised £5.1 million in funding, which will be used to expand on the success of its initial clinical trials and develop the application of its technology to the treatment of other conditions. The funding round was led

Clarendo portfolio company Cirdan the medical informatics and imaging technology company has today announced that it has acquired the Belfast-based Philips Digital and Computational Pathology business (formerly known as PathXL). Headquartered in Northern Ireland with offices in Canada and Australia, Cirdan specialises in developing technology that supports and speeds up diagnosis, primarily used by those